このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
SMS Pharmaceuticals バランスシートの健全性
財務の健全性 基準チェック /36
SMS Pharmaceuticalsの総株主資本は₹5.4B 、総負債は₹2.8Bで、負債比率は52.2%となります。総資産と総負債はそれぞれ₹10.3Bと₹5.0Bです。 SMS Pharmaceuticalsの EBIT は₹851.0Mで、利息カバレッジ比率3.6です。現金および短期投資は₹362.0Mです。
主要情報
52.2%
負債資本比率
₹2.80b
負債
| インタレスト・カバレッジ・レシオ | 3.6x |
| 現金 | ₹362.03m |
| エクイティ | ₹5.36b |
| 負債合計 | ₹4.98b |
| 総資産 | ₹10.34b |
財務の健全性に関する最新情報
Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21
SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09
Recent updates
Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09Should You Take Comfort From Insider Transactions At SMS Pharmaceuticals Limited (NSE:SMSPHARMA)?
Nov 18The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 110% And Shareholders Are Boasting About It
Oct 28What Kind Of Shareholders Hold The Majority In SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Shares?
Oct 08Are Dividend Investors Getting More Than They Bargained For With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Dividend?
Sep 17SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Aug 26SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Price Could Signal Some Risk
Aug 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Business Is Trailing The Market But Its Shares Aren't
Aug 08SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Looks Just Right
Jul 25財務状況分析
短期負債: SMSPHARMAの 短期資産 ( ₹5.3B ) が 短期負債 ( ₹3.3B ) を超えています。
長期負債: SMSPHARMAの短期資産 ( ₹5.3B ) が 長期負債 ( ₹1.7B ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: SMSPHARMAの 純負債対資本比率 ( 45.5% ) は 高い と見なされます。
負債の削減: SMSPHARMAの負債対資本比率は、過去 5 年間で44.7%から52.2%に増加しました。
債務返済能力: SMSPHARMAの負債は 営業キャッシュフロー によって 十分にカバーされていません ( 17.9% )。
インタレストカバレッジ: SMSPHARMAの負債に対する 利息支払い は EBIT ( 3.6 x coverage) によって 十分にカバーされています。